CBX3 and acute myeloid leukemia: If so, there is a need to investigate both physiological consequences of affected normal genes in relapsed/refractory AML and functional roles of the lesser known, cytogenetically unknown gene fusions like CCDC32/CBX3 so that targeted therapies can be more specific and effective.